However, the large study of Shlipak and colleagues, including 11 cohorts of the general population (with a mean age of 60 years) and 5 cohorts with CKD (mean age 55 years), found that cystatin C-based eGFR could better categorize risk than creatinine-based eGFR, especially around the threshold of 60 mL/min/1.73m2 [7], in line with recommendations of KDIGO [5]. This evidence concerns the gene CST3 and chronic kidney disease.